557 related articles for article (PubMed ID: 19766644)
21. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
22. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes.
Shirakawa J; Amo K; Ohminami H; Orime K; Togashi Y; Ito Y; Tajima K; Koganei M; Sasaki H; Takeda E; Terauchi Y
J Biol Chem; 2011 Jul; 286(29):25467-76. PubMed ID: 21613229
[TBL] [Abstract][Full Text] [Related]
23. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
24. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
25. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
Duez H; Smith AC; Xiao C; Giacca A; Szeto L; Drucker DJ; Lewis GF
Endocrinology; 2009 Jan; 150(1):56-62. PubMed ID: 18801896
[TBL] [Abstract][Full Text] [Related]
26. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
27. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function.
Shu L; Matveyenko AV; Kerr-Conte J; Cho JH; McIntosh CH; Maedler K
Hum Mol Genet; 2009 Jul; 18(13):2388-99. PubMed ID: 19386626
[TBL] [Abstract][Full Text] [Related]
28. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
Kim SJ; Nian C; Doudet DJ; McIntosh CH
Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
[TBL] [Abstract][Full Text] [Related]
30. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
Irwin N; Hunter K; Montgomery IA; Flatt PR
Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
[TBL] [Abstract][Full Text] [Related]
31. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis.
Pamir N; Lynn FC; Buchan AM; Ehses J; Hinke SA; Pospisilik JA; Miyawaki K; Yamada Y; Seino Y; McIntosh CH; Pederson RA
Am J Physiol Endocrinol Metab; 2003 May; 284(5):E931-9. PubMed ID: 12540373
[TBL] [Abstract][Full Text] [Related]
32. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
33. Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin.
Iida A; Seino Y; Fukami A; Maekawa R; Yabe D; Shimizu S; Kinoshita K; Takagi Y; Izumoto T; Ogata H; Ishikawa K; Ozaki N; Tsunekawa S; Hamada Y; Oiso Y; Arima H; Hayashi Y
Diabetologia; 2016 Jul; 59(7):1533-1541. PubMed ID: 27053237
[TBL] [Abstract][Full Text] [Related]
34. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
36. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
38. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
39. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
[TBL] [Abstract][Full Text] [Related]
40. Expression of glucagon-like peptide-1 receptor and glucose‑dependent insulinotropic polypeptide receptor is regulated by the glucose concentration in mouse osteoblastic MC3T3-E1 cells.
Aoyama E; Watari I; Podyma-Inoue KA; Yanagishita M; Ono T
Int J Mol Med; 2014 Aug; 34(2):475-82. PubMed ID: 24866833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]